IGF-1 LR3

IGF-1 LR3 Peptide Detailed Overview

IGF-1 LR3 is a highly significant compound within the Growth Hormone axis research bracket, designed to stimulate and analyze the intricate cascades of systemic metabolic regeneration and endocrine pulsing.

Pharmacological Profile

Parameter	Value
Molecular Formula	C400H625N111O115S6
Molecular Weight	9111.6 g/mol
Assay Purity	>98.5%
Appearance	Lyophilized white cake

Figure 1: Conceptual Binding Mechanism of IGF-1 LR3

Molecular Methodology

The sequential action framework observed in experimental diagnostics:

1. Resists binding to IGF Binding Proteins (IGFBPs) due to the Arg3 substitution.
2. Remains active in the bloodstream for roughly 20-30 hours, greatly outlasting native IGF-1.
3. Engages the IGF-1 receptor (IGF-1R) heavily on skeletal muscle tissues.
4. Initiates PI3K/AKT and MAPK signaling cascades.
5. Stimulates hyperplasia (the creation of entirely new muscle cells).

Figure 2: Empirical Systemic Response Profile

Identified Research Parameters

• Vector Observation: Provides an estimated 200-300% efficiency increase over endogenous IGF-1.
• Trial Output: Promotes glucose transport into muscle fibers independently of insulin.
• Diagnostic Core: Heavily researched for reversing age-related sarcopenia.

Long-Acting Insulin-Like Growth Factor-1

IGF-1 LR3 (Long R3 IGF-1) is an 83-amino acid analogue of human IGF-1 with two key modifications: an arginine substitution at position 3 (replacing glutamic acid) and a 13-amino acid N-terminal extension peptide. These changes reduce IGF-binding protein (IGFBP) affinity by over 100-fold, dramatically increasing the proportion of free, bioactive IGF-1 in circulation. Native IGF-1 is 95–99% bound to IGFBPs (primarily IGFBP-3 in the 150-kDa ternary complex), limiting its bioavailability. IGF-1 LR3 effectively removes this regulatory buffer.

1. IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) with affinity equivalent to native IGF-1, activating PI3K/Akt and Ras/MAPK mitogenic signaling cascades.
2. PI3K/Akt activation drives mTOR/p70S6K-mediated protein synthesis, the primary signaling pathway for skeletal muscle hypertrophy.
3. MAPK/ERK activation promotes satellite cell proliferation and differentiation, increasing the myonuclear domain available for muscle fiber growth.
4. The virtual absence of IGFBP binding means the half-life is extended to 20–30 hours (vs. 12–15 hours for native IGF-1) and bioavailability approaches 100%.
5. IGF-1 LR3 also potently inhibits apoptosis through Akt-mediated phosphorylation of BAD and caspase-9, providing tissue-protective anti-apoptotic effects.

Research Applications & Considerations

• Muscle Hypertrophy: IGF-1 LR3 is the most extensively studied IGF-1 analogue in muscle biology research, producing dose-dependent hypertrophy in both Type I and Type II muscle fibers.
• Hyperplasia: Unlike most anabolic agents that cause hypertrophy (enlargement of existing fibers), IGF-1 promotes satellite cell fusion and potentially true hyperplasia (new fiber formation).
• Hypoglycemia Risk: IGF-1 LR3 activates insulin receptor substrate-1 (IRS-1) and promotes glucose uptake. Hypoglycemia is the primary acute safety concern in research protocols.
• Dosing: Research doses range from 20–100 μg/day SC. Post-prandial administration reduces hypoglycemia risk. Typical cycle length: 4–6 weeks on, 4 weeks off.
• Storage: Reconstitute in 0.6% acetic acid for maximum stability. Refrigerate at 2–8°C. The acidic reconstitution prevents aggregation and deamidation.